EMCIF Retreat:
Driving Global Cancer Focused Innovation at Lightspeed
at the Ritz Carlton, Laguna Niguel, CA
Highlights
Over the summer, the Emerging Markets Cancer Ignition (EMCIF) team was honored to host an EMCIF
Retreat: Driving Global Cancer Focused Innovation at the Ritz Carlton Laguna Niguel in Southern California. In recognition of our collective passion for developing sustainable & equitable access to innovative cancer solutions our distinguished group of thought leaders included:
Julie R. Gralow, MD - Chief Medical Officer of ASCO
Dr. Gralow is the Chief Medical Officer (CMO) and Executive Vice President of ASCO, and
brings to her role deep expertise in patient care, research, education, and global health.
Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the
Women’s Empowerment Cancer Advocacy Network (WE CAN), she supports patient
advocates in low- and middle-resource countries. Dr. Gralow received the ASCO
Humanitarian Award in 2018 for her work in empowering women cancer patients and
survivors globally.
Kim Kamdar, Ph.D. - Partner at Domain Associates
Dr. Kamdar is a Partner at Domain Associates. Kim has a background in small molecule
drug discovery. She has been involved in cutting-edge therapeutic start-ups and has been
a major part of identifying companies with promising molecular and companion
diagnostics to support personalized medicine. Kim is currently Chair of the board of
directors of Aspen Neuroscience and co-founder and Chair of Seraphina Therapeutics and
Truvian Sciences. She serves on the boards of Epic Sciences, Evofem Biosciences, Sera
Prognostics and Singular Genomics. Kim is the author of ten papers as well as the inventor
on seven patents.
Todd Binder, MBA. - CEO Neuvogen
Todd Binder is Chief Executive Officer and Member of the Board of Directors of Neuvogen,
and leads the company’s overall strategy to serve patients through the development of
treatments for cancer. Prior to NEUVOGEN, he served as Chief Financial Officer of ZetaRx,
a CAR T-Cell company where he gained a deep understanding of the promise of cellular
immunotherapies. Previously, Mr. Binder spent decades advising and investing in
preclinical and clinical stage biotechnology companies. He has served as an Officer in the
US Army, and as a consultant at McKinsey and Company.
Who Attended?
A select group of approximately 50 entrepreneurs, scientists, physicians, and
philanthropists who are passionate and energized about our core mission.
